Semimechanistic Physiologically‐Based Pharmacokinetic/Pharmacodynamic Model Informing Epcoritamab Dose Selection for Patients With B‐Cell Lymphomas

Epcoritamab is a CD3xCD20 bispecific antibody (bsAb) that induces T‐cell–mediated cytotoxicity against CD20‐positive B cells. Target engagement and crosslinking of CD3 and CD20 (trimer formation) leads to activation and expansion of T cells and killing of malignant B cells. The primary objective of...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Tommy, Hiemstra, Ida H., Chiu, Christopher, Oliveri, Roberto S., Elliott, Brian, DeMarco, Dena, Salcedo, Theodora, Egerod, Frederikke Lihme, Sasser, Kate, Ahmadi, Tahamtan, Gupta, Manish
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827893/
https://www.ncbi.nlm.nih.gov/pubmed/35996883
http://dx.doi.org/10.1002/cpt.2729

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827893/
https://www.ncbi.nlm.nih.gov/pubmed/35996883
http://dx.doi.org/10.1002/cpt.2729

Ejemplares similares